Viatris - 45 Year Stock Price History | VTRS
Historical daily share price chart and data for Viatris since 1980 adjusted for splits and dividends. The latest closing stock price for Viatris as of August 22, 2025 is 10.65.
- The all-time high Viatris stock closing price was 62.89 on April 24, 2015.
- The Viatris 52-week high stock price is 13.55, which is 27.2% above the current share price.
- The Viatris 52-week low stock price is 6.85, which is 35.7% below the current share price.
- The average Viatris stock price for the last 52 weeks is 10.41.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Viatris Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2025 |
9.2503 |
11.9567 |
11.9567 |
7.0772 |
10.6500 |
-11.14% |
| 2024 |
11.0600 |
10.5322 |
12.8712 |
9.4891 |
11.9855 |
19.68% |
| 2023 |
9.1511 |
10.0329 |
10.8088 |
8.0058 |
10.0144 |
2.06% |
| 2022 |
9.5559 |
12.0242 |
13.0311 |
7.3953 |
9.8125 |
-14.29% |
| 2021 |
12.1293 |
15.3307 |
15.3307 |
10.2303 |
11.4488 |
-26.12% |
| 2020 |
13.9711 |
17.0755 |
18.8947 |
10.9647 |
15.4961 |
-6.77% |
| 2019 |
18.4345 |
23.0871 |
26.5435 |
13.8919 |
16.6207 |
-26.64% |
| 2018 |
31.3542 |
35.6477 |
39.3935 |
21.6731 |
22.6571 |
-35.24% |
| 2017 |
31.1775 |
32.3401 |
37.4420 |
24.5011 |
34.9862 |
10.90% |
| 2016 |
35.9693 |
44.0572 |
44.7270 |
28.2304 |
31.5462 |
-29.44% |
| 2015 |
47.8272 |
46.5958 |
62.8940 |
32.3814 |
44.7105 |
-4.08% |
| 2014 |
41.3646 |
35.2094 |
48.4729 |
34.9448 |
46.6124 |
29.88% |
| 2013 |
28.0186 |
22.9051 |
36.7971 |
22.7728 |
35.8875 |
58.11% |
| 2012 |
19.2858 |
18.3158 |
23.4013 |
17.0672 |
22.6984 |
27.91% |
| 2011 |
17.7613 |
17.9107 |
20.8627 |
13.3627 |
17.7453 |
1.56% |
| 2010 |
16.0639 |
15.4796 |
19.2254 |
13.9415 |
17.4724 |
14.65% |
| 2009 |
11.7856 |
8.2855 |
15.7442 |
8.1532 |
15.2398 |
86.35% |
| 2008 |
9.6832 |
11.4774 |
12.7343 |
4.7712 |
8.1780 |
-29.66% |
| 2007 |
14.8330 |
16.4707 |
18.6603 |
10.9564 |
11.6262 |
-29.13% |
| 2006 |
17.2431 |
16.2512 |
20.2490 |
15.5715 |
16.4050 |
1.15% |
| 2005 |
14.7462 |
14.1098 |
17.5074 |
12.4755 |
16.2187 |
14.17% |
| 2004 |
16.4075 |
20.0621 |
20.6211 |
11.7641 |
14.2062 |
-29.58% |
| 2003 |
17.3736 |
12.5254 |
22.4632 |
12.5254 |
20.1739 |
63.79% |
| 2002 |
11.0282 |
12.6228 |
12.6228 |
8.7957 |
12.3172 |
-5.80% |
| 2001 |
10.1431 |
8.5021 |
13.2190 |
7.2322 |
13.0761 |
50.75% |
| 2000 |
8.7177 |
8.2654 |
10.9736 |
5.7846 |
8.6743 |
1.56% |
| 1999 |
8.1483 |
10.0153 |
10.4326 |
5.8489 |
8.5409 |
-18.78% |
| 1998 |
9.1277 |
6.6124 |
11.6903 |
5.8502 |
10.5161 |
52.39% |
| 1997 |
5.9269 |
5.3292 |
8.2030 |
3.7358 |
6.9008 |
28.52% |
| 1996 |
5.6583 |
7.2407 |
7.2407 |
4.4978 |
5.3696 |
-27.81% |
| 1995 |
6.4030 |
5.3584 |
7.6857 |
5.1513 |
7.4384 |
33.03% |
| 1994 |
4.7994 |
4.8888 |
6.0964 |
3.2238 |
5.5914 |
9.30% |
| 1993 |
5.6085 |
6.0655 |
7.3033 |
4.1151 |
5.1156 |
-18.00% |
| 1992 |
4.3071 |
4.0069 |
6.2422 |
3.0897 |
6.2387 |
55.23% |
| 1991 |
2.6058 |
1.8321 |
4.0190 |
1.5786 |
4.0190 |
111.38% |
| 1990 |
1.8073 |
2.0820 |
2.1478 |
1.3014 |
1.9013 |
-10.56% |
| 1989 |
1.1126 |
0.7727 |
2.1870 |
0.6638 |
2.1259 |
175.13% |
| 1988 |
0.8800 |
0.7567 |
1.1350 |
0.7053 |
0.7727 |
8.30% |
| 1987 |
1.1699 |
0.9752 |
1.4467 |
0.6665 |
0.7135 |
-25.19% |
| 1986 |
1.5099 |
1.5361 |
2.3042 |
0.9281 |
0.9537 |
-39.18% |
| 1985 |
1.7851 |
2.0908 |
3.0509 |
1.1734 |
1.5681 |
-27.59% |
| 1984 |
1.9835 |
1.6535 |
2.9976 |
1.1841 |
2.1655 |
27.68% |
| 1983 |
1.6777 |
1.5895 |
2.7522 |
1.1734 |
1.6961 |
10.42% |
| 1982 |
1.3412 |
1.4295 |
1.8455 |
0.7574 |
1.5361 |
6.67% |
| 1981 |
1.1868 |
0.7040 |
2.3895 |
0.6081 |
1.4401 |
107.69% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$12.417B |
$14.739B |
|
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
|
